[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2-, GRPR+ Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: [68Ga]Ga-NeoB|DRUG: [177Lu]Lu-NeoB|DRUG: Ribociclib|DRUG: fulvestrant|OTHER: Goserelin
Sponsor: Novartis Pharmaceuticals